TAG Innovation

TAG Innovation is a French biotechnology company specializing in neuroregeneration, with a primary focus on restoring functional connectivity in the central nervous system. Spun out from the Institut de la Vision in Paris, the company leverages a proprietary platform based on axon guidance molecules to promote the regrowth of damaged axons, particularly in the eye. Their lead research programs target ophthalmic conditions such as glaucoma and traumatic optic nerve injuries, where they aim to stimulate retinal ganglion cell axons to reconnect with their targets in the brain. By transitioning from traditional neuroprotection to active axonal repair, TAG Innovation seeks to provide disease-modifying treatments for vision loss and other neurological disorders.